A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema

Trial Profile

A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Aflibercept (Primary) ; Bevacizumab (Primary) ; Ranibizumab (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 23 Jan 2014 According to ClinicalTrials.gov record planned number of patients changed from 400 to 300.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top